
The results also support that the drug should be stored in ordinary freezers and not at ultra-cold temperatures.
The COVID-19 vaccine developed by Pfizer and German drugmaker BioNTech is 85% effective after a single dose, according to an Israeli study published yesterday in The Lancet.
The research was conducted at the Sheba Medical Center in Israel with a sample of 7,000 healthcare workers and resulted in an 85% reduction in symptomatic patients 15 to 28 days after receiving the first dose.
Pfizer indicated in its initial clinical study of the vaccine that the drug provided 95% effectiveness in symptomatic patients only if a second dose of the vaccine was received 21 days after the first dose.
However, the Puerto Rico Department of Health has not commented on the results of this study, which was published yesterday. For the time being, the vaccination process on the island continues with the administration of two doses. In the case of the Pfizer vaccine, the second dose must be administered within 21 days, while the Moderna drug must be administered within 28 days.
The Israeli study also found that the first dose of the COVID-19 vaccine prevented asymptomatic infections with a 75% reduction.
In fact, the research also shed light on how safely the vaccine should be stored and its temperatures. Pfizer stated that the drug should be stored in ultra-cold freezers, but the Israeli study suggests, according to the results, that it can be stored in ordinary freezers.
The results of this study support the European Union’s decision to extend the waiting time between the first and second doses of the vaccine to 12 weeks.
According to Forbes magazine, Israel’s government vaccination campaign is the fastest in the world with almost half of its population vaccinated with a single dose.
